VERA THERAPEUTICS INC (VERA) Stock Earnings & Estimates
USA - NASDAQ:VERA - US92337R1014 - Common Stock
30.2 USD
-1.03 (-3.3%)
30.2 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 473.68% | N/A 143.84% | N/A 55.57% | N/A 34.96% | N/A 23.56% | N/A 10.49% | ||||||
| EBITDA YoY % growth | -11.08M | -47.81M -331.50% | -34.22M 28.43% | N/A -126.53% | N/A -27.63% | -167.065M -68.85% | N/A -73.51% | N/A -2.90% | N/A 30.43% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.59M | -48.06M -314.67% | -34.4M 28.42% | -90.9M -164.24% | -102.012M -12.22% | -167.17M -63.87% | N/A -77.91% | N/A -8.21% | N/A 26.03% | N/A 94.46% | N/A 1,591.90% | N/A 109.00% | N/A 47.85% | N/A 20.17% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -13.71 | -3.35 75.57% | -2.31 31.04% | -2.75 -19.05% | N/A -60.44% | N/A -6.16% | N/A 31.76% | N/A 118.29% | N/A 386.08% | N/A 52.03% | N/A 42.56% | N/A 21.25% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.17 -38.00% | -1.20 -67.04% | -1.25 -53.81% | -1.33 -10.62% | -1.35 -15.22% | -1.05 12.36% |
| Revenue Q2Q % growth | 2.564M | 26.535M | ||||
| EBITDA Q2Q % growth | -75.958M -52.68% | -74.102M -51.82% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -77.305M -55.23% | -80.102M -63.76% | -87.318M -52.67% | -93.503M -16.67% | -98.04M -26.82% | -87.347M -9.04% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -1.20 -93.55% | -0.84 | -0.36 | -43.18% |
| Q1 2025 Q2Q % growth | -0.81 -44.64% | -0.75 | -0.06 | -8.04% |
| Q4 2024 Q2Q % growth | -0.72 -20.00% | -0.85 | 0.13 | 15.67% |
| Q3 2024 Q2Q % growth | -0.85 -88.89% | -0.67 | -0.18 | -26.69% |
| Q2 2024 Q2Q % growth | -0.62 -34.78% | -0.57 | -0.05 | -8.54% |
| Q1 2024 Q2Q % growth | -0.56 30.00% | -0.54 | -0.02 | -3.59% |
| Q4 2023 Q2Q % growth | -0.60 49.15% | -0.52 | -0.08 | -15.84% |
| Q3 2023 Q2Q % growth | -0.45 50.55% | -0.54 | 0.09 | 17.28% |
| Q2 2023 Q2Q % growth | -0.46 16.36% | -0.71 | 0.25 | 34.95% |
| Q1 2023 Q2Q % growth | -0.80 -12.68% | -0.62 | -0.18 | -29.85% |
| Q4 2022 Q2Q % growth | -1.18 -49.37% | -0.92 | -0.26 | -28.07% |
| Q3 2022 Q2Q % growth | -0.91 -152.78% | -0.74 | -0.17 | -23.62% |
| Q2 2022 Q2Q % growth | -0.55 -66.67% | -0.73 | 0.18 | 24.93% |
| Q1 2022 Q2Q % growth | -0.71 94.19% | -0.68 | -0.03 | -3.89% |
| Q4 2021 Q2Q % growth | -0.79 | -0.47 | -0.32 | -66.56% |
| Q3 2021 Q2Q % growth | -0.36 | -0.61 | 0.25 | 40.68% |
| Q2 2021 Q2Q % growth | -0.33 | -0.40 | 0.07 | 17.04% |
| Q1 2021 Q2Q % growth | -12.23 | -1.98 | -10.25 | -516.46% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 1.88% | -36.63% | 1.36% | -32.09% |
| Revenue | N/A | N/A | N/A | N/A |